This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Julie M. Plyler
New York +1 212 841 1090 Download V-card

Julie Plyler is a member of the firm’s corporate practice group and focuses on capital markets and securities transactions in the life sciences industry. She also represents companies in connection with financing transactions.

  • Represented the underwriters in a $144 million global offering of ordinary shares and ADSs of ERYTECH Pharma S.A., a France-based company developing therapies for rare forms of cancer and orphan diseases using a novel technology to encapsulate therapeutic drug substances inside red blood cells.
  • Represented the underwriters in the $80 million initial public offering of ordinary shares of Nightstar Therapeutics plc, a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases.
  • Represented the underwriters in the $67 million initial public offering and $69 million follow-on offering of ordinary shares of UroGen Pharma Ltd., an Israeli biopharmaceutical company focused on non-surgical uro-oncology treatments.

Pro Bono

  • Provides ongoing legal services and advice to Village Health Works, a 501(c)(3) nonprofit organization focused on providing quality health care in rural Burundi.